BI 3034701 vs NA-931: Early Triple Agonist vs Quadruple Ambition
By FormBlends Medical Team · Last updated: April 25, 2026
BI 3034701 is the more disciplined early-development story. NA-931 is the more ambitious one. If you think obesity winners will still come from relatively controlled multi-agonist engineering, BI 3034701 is easier to underwrite. If you think the field keeps rewarding bigger mechanism swings, NA-931 is the bolder watch.
How to Use This Comparison
Use this comparison as a decision aid, not a prescription shortcut. BI 3034701 is an early triple-agonist program, while NA-931 pushes into quadruple-mechanism territory. BI 3034701 is usually a better fit for readers who prefer an early but still relatively disciplined multi-agonist bet, while NA-931 (Bioglutide) is usually a better fit for readers watching whether more extreme receptor stacking can actually survive development. Cost also matters: BI 3034701 is listed at Early trial-stage asset; pricing unknown, while NA-931 (Bioglutide) is listed at Trial-stage asset; pricing unknown. Because this comparison is framed as an either-or decision, the safety question is which option fits your health history, side-effect tolerance, and access path.
PubMed evidence trail
Research sources used to frame this page
For BI 3034701 vs NA-931: Early Triple Agonist vs Quadruple Ambition, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
BI 3034701 vs NA-931: Early Triple Agonist vs Quadruple Ambition should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
Compare available products and select the relevant treatment page for its specific next step.
Head-to-Head Comparison
BI 3034701
Pipeline Compound
Strengths
- Backed by Boehringer and Gubra with a real obesity-development infrastructure behind it
- Represents a more disciplined early triple-agonist pathway bet
- Still early enough to improve sharply if human data is clean
Weaknesses
- Only Phase 1, so there is still major development risk
- Less headline novelty than a more aggressive receptor stack
Best For
Readers who prefer an early but still relatively disciplined multi-agonist bet.
Typical Cost
Early trial-stage asset; pricing unknown
NA-931 (Bioglutide)
Pipeline Compound
Strengths
- Quadruple-mechanism ambition makes it one of the more aggressive designs in the field
- Already Phase 2, which matters given how experimental the biology sounds
- Could become important if stacked-receptor programs keep outperforming expectations
Weaknesses
- The more ambitious the receptor stack, the more skepticism it invites on tolerability and manufacturability
- Sponsor visibility is lower than the large-cap leaders
Best For
Readers watching whether more extreme receptor stacking can actually survive development.
Typical Cost
Trial-stage asset; pricing unknown
Key Differences
- 1BI 3034701 is an early triple-agonist program, while NA-931 pushes into quadruple-mechanism territory
- 2NA-931 is further along on paper, but it also carries a more aggressive design risk
- 3Boehringer/Gubra gives BI 3034701 a stronger big-company development context
- 4This comparison is mostly about disciplined complexity versus maximal complexity
Frequently Asked Questions
What is the difference between BI 3034701 and NA-931 (Bioglutide)?
BI 3034701 is an early triple-agonist program, while NA-931 pushes into quadruple-mechanism territory. NA-931 is further along on paper, but it also carries a more aggressive design risk.
Which is more effective, BI 3034701 or NA-931 (Bioglutide)?
BI 3034701 is the more disciplined early-development story. NA-931 is the more ambitious one. If you think obesity winners will still come from relatively controlled multi-agonist engineering, BI 3034701 is easier to underwrite. If you think the field keeps rewarding bigger mechanism swings, NA-931 is the bolder watch.
How much does BI 3034701 cost compared to NA-931 (Bioglutide)?
BI 3034701 typically costs Early trial-stage asset; pricing unknown, while NA-931 (Bioglutide) typically costs Trial-stage asset; pricing unknown.
Who should choose BI 3034701 over NA-931 (Bioglutide)?
BI 3034701 is best for: Readers who prefer an early but still relatively disciplined multi-agonist bet.. NA-931 (Bioglutide) is best for: Readers watching whether more extreme receptor stacking can actually survive development..
Ready to get started?
Connect with a licensed provider who can help you decide between BI 3034701 and NA-931 (Bioglutide) based on your goals, health history, and budget.